Lite Strategy

Lite Strategy Interest Expense

The Interest Expense of Lite Strategy (LITS) as of Nov 2, 2026 is 1.03 M USD. In the previous year, Interest Expense was 3.28 M USD — a change of -68.69% (lower).

Interest Expense

1.03 MUSD

YoY

-68.69%

Last updated:

Interest Expense of Lite Strategy is 2025 1.03 M USD. Interest Expense of Lite Strategy was 2024 3.28 M USD. It decreases by -68.69% lower compared to the previous year.

The Lite Strategy Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-1.78 M USD
Jan 1, 2019
1.80 M USD
Jan 1, 2020
1.40 M USD
Jan 1, 2021
510,000.00 USD
Jan 1, 2022
280,000.00 USD
Jan 1, 2023
3.35 M USD
Jan 1, 2024
3.28 M USD
Jan 1, 2025
1.03 M USD
The Lite Strategy Interest Expense history
YEARInterest ExpenseYoY
1.03 MUSD-68.69%
3.28 MUSD-2.18%
3.35 MUSD+1,096.43%
280,000.00USD-45.10%
510,000.00USD-63.57%
1.40 MUSD-22.22%
1.80 MUSD-201.12%
-1.78 MUSD-713.79%
290,000.00USD+107.14%
140,000.00USD+75.00%
80,000.00USD0.00%
80,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Interest Expense of Lite Strategy is 1.03 M USD in 2025.

Interest Expense of Lite Strategy changed from 3.28 M USD to 1.03 M USD, representing a -68.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Lite Strategy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Lite Strategy

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Lite Strategy